title: Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258.
authors.affiliation: GSK, Wavre, Belgium. Electronic address: Nicolas.x.folschweiller@gsk.com.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Folschweiller
authors.affiliation: GSK, Wavre, Belgium.
authors.forename: Valérie
authors.initials: V
authors.lastname: Berlaimont
authors.affiliation: Discipline of Child and Adolescent Health, Sydney University and The Children's Hospital Westmead, Sydney, NSW, Australia; Vaccine Trials Group, Telethon Kids Institute, University of Western Australia, Perth, Australia.
authors.forename: S Rachel
authors.initials: SR
authors.lastname: Skinner
authors.affiliation: Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
authors.forename: Cosette M
authors.initials: CM
authors.lastname: Wheeler
authors.affiliation: GSK Pharmaceuticals India Ltd., Bangalore, India.
authors.forename: Naveen
authors.initials: N
authors.lastname: Karkada
authors.affiliation: GSK, Wavre, Belgium.
authors.forename: Frank
authors.initials: F
authors.lastname: Struyf
authors.affiliation: GSK, Wavre, Belgium.
authors.forename: Martin
authors.initials: M
authors.lastname: Ryser
mesh_terms: D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines; D002583:Uterine Cervical Neoplasms; D002578:Uterine Cervical Dysplasia
chemical_list: D053918:Papillomavirus Vaccines